The University of Vermont Medical Center is a five-campus academic medical facility under the corporate umbrella of The University of Vermont Health Network corporate that is anchored by a 562-bed hospital. UVM is located in Burlington, Vermont, and serves as both a regional referral center and a community hospital.

There are 562 beds in Fletcher Allen Health Care.

During the past decade, Fletcher Allen Health Care conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 20 clinical trials were completed, i.e. on average, 333.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fletcher Allen Health Care" #1 sponsor was "University of Vermont" with 12 trials, followed by "Acorda Therapeutics" with 5 trials sponsored, "Boston Scientific Corporation" with 5 trials sponsored, "Abbott Medical Devices" with 4 trials sponsored and "Eisai Inc." with 4 trials sponsored. Other sponsors include 54 different institutions and companies that sponsored additional 53 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fletcher Allen Health Care" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "Basilea Pharmaceutica" with 1 trials as a collaborator and "Canadian Heart Research Centre" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Fletcher Allen Health Care" are "Coronary Artery Disease" (8 trials), "Multiple Sclerosis" (5 trials), "Alzheimer's Disease" (4 trials), "Breast Cancer" (3 trials) and "Coronary Artery Stenosis" (3 trials). Many other conditions were trialed in "Fletcher Allen Health Care" in a lesser frequency.

Most popular intervention types in "Fletcher Allen Health Care" are "Drug" (61 trials), "Device" (17 trials), "Other" (4 trials), "Radiation" (3 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Fampridine-SR" (4 trials), "Carboplatin" (3 trials), "Abemaciclib" (2 trials) and "Bapineuzumab 0.5 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Fletcher Allen Health Care" are 77 trials for "All" genders, 10 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Fletcher Allen Health Care". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 70 completed trials in Fletcher Allen Health Care, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Fletcher Allen Health Care, 6 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 40 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 13 trials that are defined as “Not Applicable".